We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

7 hedge funds and large institutions have $534K invested in Scinai Immunotherapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more capital invested

Capital invested by funds: $309K → $534K (+$225K)

1.32% more ownership

Funds ownership: 11.67% → 13% (+1.3%)

22% less funds holding

Funds holding: 9 → 7 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$464K
2
SM
Sabby Management
Florida
+$69.3K
3
UBS Group
UBS Group
Switzerland
+$641
4
Morgan Stanley
Morgan Stanley
New York
+$128

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$15.7K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$14.9K
3
Credit Agricole
Credit Agricole
France
-$598
4
NC
NewSquare Capital
Pennsylvania
-$3

SCNI Hedge Fund Activity: Q3 2023 in Review

7 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2023, worth a combined $534K — up 73% from $309K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of SCNI and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $464K. The largest seller was Millennium Management, exiting entirely with an estimated $15.7K sold.

  • 7 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2023, down from 9 in Q2 2023.
  • Funds reported $534K of Scinai Immunotherapeutics stock for Q3 2023, up 73% quarter-over-quarter.
  • 1 fund opened new Scinai Immunotherapeutics positions in Q3 2023 and 3 closed out, a net change of -2 holders.
  • The largest Scinai Immunotherapeutics buyer in Q3 2023 was Armistice Capital, an estimated $464K added.
  • The largest Scinai Immunotherapeutics seller in Q3 2023 was Millennium Management, an estimated $15.7K sold.

Based on aggregated 13F filings for Q3 2023.